The 3rd Asian Pneumococcal Symposium

Program

Schedule PDF

Day 1: Thursday, December 2, 2021

Welcome Remarks09:00-09:05

Kazunori Oishi
President, Toyama Institute of Health, Japan

Session 1:
Capsular Nomenclature
09:05-09:50

Chair:
Shigetada Kawabata Osaka University Graduate School of Dentistry, Japan
SE1-1Capsule Expression among Oral Streptococci
Moon H. Nahm
University of Alabama at Birmingham, USA
SE1-2Two cases of bacteremia due to S. oralis expressing serotype 3 pneumococcal capsule
Kei Kasahara
Nara Medical University, Japan

Session 2:
Genetics and Genomics
09:50-10:40

Chair:
Jun Kurushima Gumma University, Graduate School of Medicine, Japan
SE2-1Predication of β-lactam resistance phenotype
Jie Feng
Institute of Microbiology, Chinese Academy of Sciences, China
SE2-2 Exploring pneumococcal virulence factors via molecular evolutionary analysis
Masaya Yamaguchi
Osaka University Graduate School of Dentistry, Japan

Session 3:
Pneumococcus-host Interactions
10:50-11:50

Chair:
Soichiro Kimura Toho University of Medicine, Japan
SE3-1Survival strategy of S. pneumoniae by hijacking host autophagy
Michinaga Ogawa
National Institute of Infectious Diseases, Japan
SE3-2Capsule serotype-dependent evasion of resident macrophage capture
Jing-Ren Zhang
Tsinghua University, China

Luncheon Seminar 1:
Co-sponsored by MSD K.K.
12:00-13:00

Chair:
Junichiro Nishi Kagoshima University Graduate School of Medicine and Dental Sciences, Japan
LS1-1Epidemiology of adult pneumococcal infections in Japan
Koji Kuronuma
Sapporo Medical University School of Medicine, Japan
LS1-2Current situation of pneumococcal disease in children in Japan
Naruhiko Ishiwada
Chiba University, Japan

Session 4:
Cost Effectiveness of Vaccine
13:10-13:50

Chair:
Shin Sasaki Medical Affairs, MSD, Japan
SE4-1Economic evaluation of vaccines and vaccination programs:
Guides from global and Japanese experiences
Manabu Akazawa
Meiji Pharmaceutical University, Japan
SE4-2he Health Technology Assessment of pneumococcal vaccination in Japan:
Costeffectiveness and value assessment
Ataru Igarashi
Yokohama City University School of Medicine, Japan

Poster Session 14:00-16:00

Session 1: Clinical and Epidemiological research-1 14:00-14:35

Chair:
Naruhiko Ishiwada Chiba University, Japan
P-1 Current situation of pneumococcal disease in children in Japan Epidemiological change of invasive pneumococcal disease in children after the introduction of 13-valent pneumococcal conjugate vaccine in Japan
Noriko Takeuchi
Department of Infectious Diseases, Medical Mycology Research Center, Chiba, Japan
P-2 Pneumococcal Meningitis in Adults in 2014-2018 after Introduction of Pediatric 13-valent Pneumococcal Conjugate Vaccine in Japan
Hiroyuki Fujikura
National Institute of Infectious Diseases, Tokyo, Japan
P-3 Association of Serotype with Clinical Presentation of Invasive Pneumococcal Disease in Adults, Japan
Kosuke Tamura
Department of Research Planning, Toyama Institute of Health, Toyama, Japan
P-4 Changes in the notification rate of Invasive Pneumococcal Disease in Japan during the COVID-19 pandemic: Descriptive assessment of national surveillance data
Reiko Shimbashi
Surveillance Analysis Unit, Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan
P-5 Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in patients with hematological malignancies who were outside recommended ages for routine vaccination
Kenichi Takeshita
Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan
P-6 A Novel Real-time PCR Assay Targeting lytA, piaB, and SP2020 for Identification of Streptococcus pneumoniae
Bhim Gopal Dhoubhadel
Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

Poster Viewing and Discussion 14:35-15:00

Session 2: Clinical and Epidemiological research-2 15:00-15:35

Chair:
Kei KasaharaNara Medical University, Japan
P-7 Multiple Serotypes of Pneumococci in Patients With Pneumonia and Their Associated Risk Factors in Japan
Bhim Gopal Dhoubhadel
Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan
P-8 Relationship between the Opacity Variance of Streptococcus pneumoniae Colonies and the Clinical Features of Adult Pneumococcal Pneumonia
Kazuko Yamamoto
Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
P-9 Long-term impact of introduction of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020
Haruka Maeda
Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan
P-10 Distribution and variation of serotypes and pneumococcal surface protein A clades of Streptococcus pneumoniae strains isolated from adult patients with invasive pneumococcal disease in Japan
Bin Chang
Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan
P-11 Seroepidemiological Analysis of Anti-Pneumococcal Surface Protein A (PspA) Immunoglobulin G by Clades in Japanese Population
Saeko Morino
Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan
P-12 Establishment of PspA-optimized OPA for human sera
Yuka Koizumi
The Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan

Poster Viewing and Discussion 15:35-16:00

Session 3: Basic research-1 14:00-14:41

Chair:
Yuki KinjoThe Jikei University School of Medicine, Japan
P-13 Exposure to Cigarette Smoke Enhances Pneumococcal Transmission Among Littermates in an Infant Mouse Model
Daichi Murakami
Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan
P-14 Involvement of C-type Lectin Receptors in Neutrophil-Mediated Host Defense against Pulmonary Streptococcus pneumoniae Infection
Keiko Ishii
Department of Medical Microbiology, Mycology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan
P-15 Pneumococcal surface protein A and glycolipid vaccine augments generation of long-lived plasma cells that produce antigen-specific IgG
Koji Hayashizaki
Department of Bacteriology, The Jikei University School of Medicine, Tokyo, Japan
P-16 The Roles of Transient Receptor Potential Vanilloid 1 and 4 in Pneumococcal Nasal Colonization and Invasive Disease
Masamitsu Kono
Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan
P-17 Effects of specific surface protein antigen, PspK, of non-encapsulated streptococcus pneumoniae on nasal carriage, shedding, and transmission among littermates of infant mice
Muneki Hotomi
Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan
P-18 Investigation on the virulence of non-encapsulated Streptococcus pneumoniae using liquid agar pneumonia model
Muneki Hotomi
Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan
P-19 Genetic linkage analysis identifies pneumococcal susceptibility locus in mice
Ryodai Shindo
Department of Microbiology and Infectious Disease, Toho University School of Medicine, Tokyo, Japan

Poster Viewing and Discussion 14:41-15:00

Session 4: Basic research-2 15:00-15:35

Chair:
Masaya YamaguchiOsaka University Graduate School of Dentistry, Japan
P-20 Bacteriological and molecular biological characterization of serotype 24F ST162 Streptococcus pneumoniae dependent on CO2 and temperature in Japanese children
Jun Kobayashi
Department of Laboratory Medicine, Nagano Children's Hospital, Nagano, Japan
P-21 Unbiased homeologous recombination during pneumococcal transformation allows for multiple chromosomal integration events
Jun Kurushima
Department of Bacteriology, School of Medicine, Gunma University, Gunma, Japan
P-22 Whole genome analysis of a multidrug-resistant Streptococcus pneumoniae isolate from a patient with invasive pneumococcal infection
Hiroyuki Honda
Department of Microbiology, Sapporo Medical University School of Medicine, Sapporo, Japan
P-23 Clonality Analysis of Streptococcus pneumoniae in Clinical Specimens
Delly C. Lestari
Department of Bacterial Infections, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
P-24 Bacterial transcytosis of Streptococcus pneumoniae across the host cells: An in vitro model for analysis of invasive potential
Jun-ichi Kanatani
Department of Bacteriology, Toyama Institute of Health, Toyama, Japan
P-25 Nasal epithelial barrier dysfunction involved in non-hematogenous pneumococcal dissemination to brain tissue
Yuki Takahara
Department of Oral Molecular Microbiology, Osaka University Graduate School of Dentistry, Osaka, Japan

Poster Viewing and Discussion 15:35-16:00

APS Plenary Lecture116:00-16:50

Chair:
Yuki Kinjo The Jikei University School of Medicine, Japan
PL1-1Nasal delivery of a universal protein antigen identified by CRISPRi-seq induces broad protection from pneumococcal superinfection
Jan-Willem Veening
University of Lausanne, Switzerland

Poster Award Ceremony16:50-17:00

Evening Symposium:
Clinical use of PPSV23 in adults in Asian countries
17:10-18:40

Co-sponsored by MSD K.K.

Chair:
Kazunori Oishi Toyama Institute of Health, Japan
ESY1-1Pneumococcal polysaccharide vaccine (PPSV23) for older adults in Japan
Hideki Nagai
National Hospital Organization Tokyo Hospital, Japan
ESY1-2Current status and needs for pneumococcal polysaccharide vaccine (PPSV23) in older adults of South Korea
Joon Young Song
Korea University College of Medicine, South Korea
ESY1-3Surveillance of Invasive Pneumococcal Disease in Taiwan
Cheng-Hsun Chiu
Chang Gung Memorial Hospital, Taiwan

Day 2: Friday, December 03, 2021

APS Plenary Lecture 209:00-10:00

Chair:
Kazunori Oishi Toyama Institute of Health, Japan
PL2-1Pneumococcal-Host Interactions Affecting Carriage and Transmission
Jeffrey N. Weiser
New York University, USA

Session 5:
Epidemiology 1
10:00-10:50

Chair:
Naruhiko Ishiwada Chiba University, Japan
SE5-1Global impact of PCV10/13 on invasive pneumococcal disease serotype distribution and incidence rates among children and adults: results from the PSERENADE project
Julia C. Bennet and Maria Garcia Quesada
Johns Hopkins Bloomberg School of Public Health, USA
SE5-2Dynamic changes in serotype distribution of invasive pneumococcal disease among adults after introduction of pediatric pneumococcal conjugate vaccine (PCV) in 2013–2019 in Japan
Kazunori Oishi
Toyama Institute of Health, Japan

Session 6 :
Epidemiology 2
11:00-11:50

Chair:
Kazuyoshi KawakamiTohoku University, Japan
SE6-1Molecular epidemiology of pneumococcal isolates in Japan
Satoshi Nakano
National Institute of Infectious Diseases, Japan
SE6-2Changes in molecular epidemiology in Korea after the introduction of Extended valency PCVs in Korean children
Hyunju Lee
Seoul National University Bundang Hospital, South Korea

Luncheon Seminar 2 :
Co-sponsored by SHIONOGI & CO., LTD.
12:00-13:00

Chair:
Hiroshi YotsuyanagiThe University of Tokyo, Japan
LS2-1Lessons learned from Pandemic: Similarity and difference in COVID-19 and Influenza
Kazuhiro Tateda
Toho University of Medicine, Japan

Session 7 :
Nasopharyngeal Carriage
13:10-14:00

Chair:
Shigeto HamaguchiOsaka University, Japan
SE7-1The low carriage prevalence of pneumococcus among community-dwelling older people
Konosuke Morimoto
Nagasaki University, Japan
SE7-2Using community vaccine type pneumococcal carriage to evaluate of reduced dosing PCV schedules in Vietnam
Lay-Myint Yoshida
Nagasaki University, Japan

Session 8 :
Sequential Administration of PCV13-PPSV23
14:00-14:40

Chair:
Satoshi IwataNational Cancer Center Hospital, Japan
SE8-1The immunogenicity of sequential administration of PCV13/ PPSV23 in pneumococcal vaccine-naïve adults ≥ 65 years of age
Momoyo Azuma
Tokushima University Hospital, Japan
SE8-2Pneumococcal vaccination in adult allogeneic hematopoietic stem cell transplant recipients
Keiji Okinaka
National Cancer Center Hospital, Japan

SSession 9 :
Novel Vaccines
14:50-16:10

Chairs:
Muneki Hotomi Wakayama Medical University, Japan
Yukihiro Akeda National Institute of Infectious Diseases, Japan
SE9-1Delivery of Streptococcus pneumoniae capsular polysaccharides by recombinant attenuated Salmonella vaccines
Qingke Kong
South Western University, China
SE9-2Broad-spectrum vaccine candidate using bivalent recombinant fusion proteins of Pneumococcal Surface Protein A (PspA) against Streptococcus pneumoniae
Hiroki Nakayama
The Research Foundation for Microbial Diseases of Osaka University, Japan
SE9-3Phase 3 trial to evaluate safety, tolerability and immunogenicity of V114 followed by 23-valent pneumococcal polysaccharide vaccine 6 months later in at-risk adults aged 18–49 years (PNEU-DAY)
Luwy Musey
Merck & Co., Inc., USA
SE9-4 Pivotal Study of the Safety, Tolerability and Immunogenicity of PCV20 in Adults
Wendy Watson
Pfizer, Inc,, USA

Joint Session:
Future outlooks of prevention of respiratory infectious diseases: New modalities and scheme
16:30-18:00

Co-Sponsored by the 25th JSV & Sanofi K.K.

Chairs:
Ken J. IshiiDivision of Vaccine Science, Department of Microbiology, and Immunology, The Institute of Medical Science, The University of Tokyo, Japan
Kazunori OishiToyama Institute of Health, Japan
JSE-1Future Perspectives of Research and Development in Infectious Disease Prevention and Future Expectations of Clinical Applications
Norio Ohmagari
National Center for Global Health and Medicine, Japan
JSE-2Past, now and future of monoclonal antibodies: From treatment to prevention in infectious disease
Susanna Esposito
Pediatrics at the Faculty of Medicine and Surgery of the University of Parma, Italy
Secretariat
President Office, Toyama Institute of Health
17-1, Nakataikoyama, Imizu City, Toyama
TEL: +81-766-56-5506
FAX: +81-766-56-7326
E-mail: aps2021@ace.ocn.ne.jp